cagrisema semaglutide Weight loss medicine is entering a new phase. is one of the most talked-about emerging therapies right now—and for good reason. This dual-agonist approach combines: 🧬 (GLP-1) 🧬 Cagrilintide (amylin CagriSema outperforms Ozempic in Phase

Mechanisms of the NAD+ salvage pathway in enhancing skeletal muscle function

Gianturco S, Ramprasad M, Lin A, Song R, Bradley W

GLP-1 therapy reshapes metabolism in parallel with weight loss, improving insulin signaling and fat oxidation directly via receptor activation, not just as a consequence of eating less

Filippello A, Di Mauro S, Scamporrino A, Malaguarnera R, Torrisi SA, Leggio GM, et al

Researchers wanted to determine whether the same genetic changes also affected GLP-1, a hormone released from the gut that helps control blood sugar after eating by stimulating insulin production, slowing stomach emptying, and reducing appetite